Compare $DMAC vs $MYGN | Chartloom

Compare

$DMAC vs $MYGN

DiaMedica Therapeutics Inc · Myriad Genetics Inc

DMAC

DiaMedica Therapeutics Inc

MYGN

Myriad Genetics Inc

Compare $DMAC vs $MYGN

Comparing DiaMedica Therapeutics Inc and Myriad Genetics Inc

DMACDiaMedica Therapeutics Inc

MYGNMyriad Genetics Inc

DMACDiaMedica Therapeutics Inc

Market cap

$449M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

5.0%

52W performance

19.7%

FCF yield

-7.0%

MYGNMyriad Genetics Inc

Market cap

$407M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

0.50x

Rev growth (TTM)

-3.2%

YTD performance

-29.8%

52W performance

-43.6%

FCF yield

-3.5%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

DMAC

MYGN

Detailed metrics comparison

DMAC

DiaMedica Therapeutics Inc

MYGN

Myriad Genetics Inc

Market Cap

DMAC$449M

MYGN$407M

Enterprise Value

DMAC$444M

MYGN$413M

Price

DMAC$8.33

MYGN$4.31

P/E Ratio

DMACN/A

MYGNN/A

P/S Ratio

DMAC0.00x

MYGN0.50x

EV/Sales

DMAC0.00x

MYGN0.51x

EV/EBITDA

DMAC0.00x

MYGN49.97x

P/B Ratio

DMAC11.58x

MYGN1.43x

P/FCF Ratio

DMACN/A

MYGNN/A

EV/FCF

DMAC-14.07x

MYGN-29.05x

PEG Ratio

DMACN/A

MYGNN/A

Forward P/E (NTM)

DMACN/A

MYGNN/A

Forward P/S (NTM)

DMACN/A

MYGN0.50x

Revenue (TTM)

DMAC$0

MYGN$807M

Revenue Growth (YoY)

DMACN/A

MYGN-3.2%

Forward Rev Growth

DMAC306.4%

MYGN5.6%

Gross Margin (TTM)

DMAC0.0%

MYGN68.8%

Operating Margin (TTM)

DMAC0.0%

MYGN0.0%

EBITDA Margin (TTM)

DMAC0.0%

MYGN-5.0%

Net Margin (TTM)

DMAC0.0%

MYGN-14.0%

FCF Margin (TTM)

DMACN/A

MYGN-1.8%

Net Income (TTM)

DMAC$-38M

MYGN$-113M

FCF (TTM)

DMAC$-32M

MYGN$-14M

EPS (TTM)

DMAC-$0.70

MYGN-$1.19

ROE (TTM)

DMAC-7768.0%

MYGN-3259.0%

ROA (TTM)

DMAC-6936.0%

MYGN-1639.0%

ROIC (TTM)

DMAC-7766.0%

MYGN-2418.0%

Cash

DMAC$5M

MYGN$115M

Debt

DMAC$9K

MYGN$121M

Net Cash/Debt

DMAC$5M

MYGN$-6M

Current Ratio (TTM)

DMAC6.72x

MYGN2.21x

Quick Ratio (TTM)

DMAC6.63x

MYGN1.72x

Debt/Equity (TTM)

DMAC0.00x

MYGN0.40x

Debt/Assets (TTM)

DMAC0.0%

MYGN0.0%

Interest Coverage (TTM)

DMACN/A

MYGNN/A

Net Debt/EBITDA (TTM)

DMAC0.00x

MYGN0.00x

Beta

DMAC0.96

MYGN1.68

52W Performance

DMAC19.7%

MYGN-43.6%

YTD Performance

DMAC5.0%

MYGN-29.8%

% from 52W High

DMAC-20.1%

MYGN-49.8%

% from 52W Low

DMAC58.8%

MYGN57.3%

Asset Turnover (TTM)

DMAC0.00x

MYGN1.17x

FCF Yield (TTM)

DMAC-7.0%

MYGN-3.5%

Earnings Yield (TTM)

DMAC-8.4%

MYGN-27.7%

Dividend Yield (TTM)

DMACN/A

MYGNN/A

Rule of 40

DMAC0.0

MYGN-4.9

EV/GP/RG

DMACN/A

MYGN1.67

Ticker research

View DMAC research View MYGN research

Metric	DMAC DiaMedica Therapeutics Inc	MYGN Myriad Genetics Inc
Market & Valuation
Market Cap	$449M	$407M
Enterprise Value	$444M	$413M
Price	$8.33	$4.31
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	0.50x
EV/Sales	0.00x	0.51x
EV/EBITDA	0.00x	49.97x
P/B Ratio	11.58x	1.43x
P/FCF Ratio	N/A	N/A
EV/FCF	-14.07x	-29.05x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	0.50x
Revenue & Growth
Revenue (TTM)	$0	$807M
Revenue Growth (YoY)	N/A	-3.2%
Forward Rev Growth	306.4%	5.6%
Profitability
Gross Margin (TTM)	0.0%	68.8%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-5.0%
Net Margin (TTM)	0.0%	-14.0%
FCF Margin (TTM)	N/A	-1.8%
Net Income (TTM)	$-38M	$-113M
FCF (TTM)	$-32M	$-14M
EPS (TTM)	-$0.70	-$1.19
ROE (TTM)	-7768.0%	-3259.0%
ROA (TTM)	-6936.0%	-1639.0%
ROIC (TTM)	-7766.0%	-2418.0%
Financial Health
Cash	$5M	$115M
Debt	$9K	$121M
Net Cash/Debt	$5M	$-6M
Current Ratio (TTM)	6.72x	2.21x
Quick Ratio (TTM)	6.63x	1.72x
Debt/Equity (TTM)	0.00x	0.40x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.96	1.68
52W Performance	19.7%	-43.6%
YTD Performance	5.0%	-29.8%
% from 52W High	-20.1%	-49.8%
% from 52W Low	58.8%	57.3%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	1.17x
FCF Yield (TTM)	-7.0%	-3.5%
Earnings Yield (TTM)	-8.4%	-27.7%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-4.9
EV/GP/RG	N/A	1.67
Ticker research	View DMAC research	View MYGN research

Valuation

P/S Ratio

DMAC

0.00x

MYGN

0.50x

EV/FCF

MYGN

-29.05x

DMAC

-14.07x

Growth & revenue

Revenue Growth TTM

MYGN

-3.2%

Forward Revenue Growth

DMAC

306.4%

MYGN

5.6%

Profitability & performance

Gross Margin

MYGN

68.8%

DMAC

0.0%

ROE

MYGN

-3259.0%

DMAC

-7768.0%

FCF Yield %

MYGN

-3.5%

DMAC

-7.0%

52-Week Performance

DMAC

19.7%

MYGN

-43.6%

Detailed metrics comparison

DMAC

DiaMedica Therapeutics Inc

MYGN

Myriad Genetics Inc

Market Cap

DMAC$449M

MYGN$407M

Enterprise Value

DMAC$444M

MYGN$413M

Price

DMAC$8.33

MYGN$4.31

P/E Ratio

DMACN/A

MYGNN/A

P/S Ratio

DMAC0.00x

MYGN0.50x

EV/Sales

DMAC0.00x

MYGN0.51x

EV/EBITDA

DMAC0.00x

MYGN49.97x

P/B Ratio

DMAC11.58x

MYGN1.43x

P/FCF Ratio

DMACN/A

MYGNN/A

EV/FCF

DMAC-14.07x

MYGN-29.05x

PEG Ratio

DMACN/A

MYGNN/A

Forward P/E (NTM)

DMACN/A

MYGNN/A

Forward P/S (NTM)

DMACN/A

MYGN0.50x

Revenue (TTM)

DMAC$0

MYGN$807M

Revenue Growth (YoY)

DMACN/A

MYGN-3.2%

Forward Rev Growth

DMAC306.4%

MYGN5.6%

Gross Margin (TTM)

DMAC0.0%

MYGN68.8%

Operating Margin (TTM)

DMAC0.0%

MYGN0.0%

EBITDA Margin (TTM)

DMAC0.0%

MYGN-5.0%

Net Margin (TTM)

DMAC0.0%

MYGN-14.0%

FCF Margin (TTM)

DMACN/A

MYGN-1.8%

Net Income (TTM)

DMAC$-38M

MYGN$-113M

FCF (TTM)

DMAC$-32M

MYGN$-14M

EPS (TTM)

DMAC-$0.70

MYGN-$1.19

ROE (TTM)

DMAC-7768.0%

MYGN-3259.0%

ROA (TTM)

DMAC-6936.0%

MYGN-1639.0%

ROIC (TTM)

DMAC-7766.0%

MYGN-2418.0%

Cash

DMAC$5M

MYGN$115M

Debt

DMAC$9K

MYGN$121M

Net Cash/Debt

DMAC$5M

MYGN$-6M

Current Ratio (TTM)

DMAC6.72x

MYGN2.21x

Quick Ratio (TTM)

DMAC6.63x

MYGN1.72x

Debt/Equity (TTM)

DMAC0.00x

MYGN0.40x

Debt/Assets (TTM)

DMAC0.0%

MYGN0.0%

Interest Coverage (TTM)

DMACN/A

MYGNN/A

Net Debt/EBITDA (TTM)

DMAC0.00x

MYGN0.00x

Beta

DMAC0.96

MYGN1.68

52W Performance

DMAC19.7%

MYGN-43.6%

YTD Performance

DMAC5.0%

MYGN-29.8%

% from 52W High

DMAC-20.1%

MYGN-49.8%

% from 52W Low

DMAC58.8%

MYGN57.3%

Asset Turnover (TTM)

DMAC0.00x

MYGN1.17x

FCF Yield (TTM)

DMAC-7.0%

MYGN-3.5%

Earnings Yield (TTM)

DMAC-8.4%

MYGN-27.7%

Dividend Yield (TTM)

DMACN/A

MYGNN/A

Rule of 40

DMAC0.0

MYGN-4.9

EV/GP/RG

DMACN/A

MYGN1.67

Ticker research

View DMAC research View MYGN research

Metric	DMAC DiaMedica Therapeutics Inc	MYGN Myriad Genetics Inc
Market & Valuation
Market Cap	$449M	$407M
Enterprise Value	$444M	$413M
Price	$8.33	$4.31
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	0.50x
EV/Sales	0.00x	0.51x
EV/EBITDA	0.00x	49.97x
P/B Ratio	11.58x	1.43x
P/FCF Ratio	N/A	N/A
EV/FCF	-14.07x	-29.05x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	0.50x
Revenue & Growth
Revenue (TTM)	$0	$807M
Revenue Growth (YoY)	N/A	-3.2%
Forward Rev Growth	306.4%	5.6%
Profitability
Gross Margin (TTM)	0.0%	68.8%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-5.0%
Net Margin (TTM)	0.0%	-14.0%
FCF Margin (TTM)	N/A	-1.8%
Net Income (TTM)	$-38M	$-113M
FCF (TTM)	$-32M	$-14M
EPS (TTM)	-$0.70	-$1.19
ROE (TTM)	-7768.0%	-3259.0%
ROA (TTM)	-6936.0%	-1639.0%
ROIC (TTM)	-7766.0%	-2418.0%
Financial Health
Cash	$5M	$115M
Debt	$9K	$121M
Net Cash/Debt	$5M	$-6M
Current Ratio (TTM)	6.72x	2.21x
Quick Ratio (TTM)	6.63x	1.72x
Debt/Equity (TTM)	0.00x	0.40x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.96	1.68
52W Performance	19.7%	-43.6%
YTD Performance	5.0%	-29.8%
% from 52W High	-20.1%	-49.8%
% from 52W Low	58.8%	57.3%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	1.17x
FCF Yield (TTM)	-7.0%	-3.5%
Earnings Yield (TTM)	-8.4%	-27.7%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-4.9
EV/GP/RG	N/A	1.67
Ticker research	View DMAC research	View MYGN research